Claude Libert

Summary

Publications

  1. Timmermans S, Van Montagu M, Libert C. Complete overview of protein-inactivating sequence variations in 36 sequenced mouse inbred strains. Proc Natl Acad Sci U S A. 2017;114:9158-9163 pubmed publisher
    ..be) and allow a global, better interpretation of genetic background effects and a source of naturally defective alleles in these 36 sequenced classical and high-priority mouse inbred strains. ..
  2. Timmermans S, Libert C. Easy Access to and Applications of the Sequences of All Protein-Coding Genes of All Sequenced Mouse Strains. Trends Genet. 2018;34:899-902 pubmed publisher
    ..We provide an insight into the advantages of using these databases. ..
  3. Souffriau J, Eggermont M, Van Ryckeghem S, Van Looveren K, Van Wyngene L, Van Hamme E, et al. A screening assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) that are effective against acute inflammation. Sci Rep. 2018;8:12894 pubmed publisher
    ..A screening pipeline for SEDIGRAM may assist the search for compounds that promote GR dimerization and limit overwhelming acute inflammatory responses. ..
  4. Timmermans S, Souffriau J, Vandewalle J, Van Wyngene L, Van Looveren K, Vanderhaeghen T, et al. Using the inbred mouse strain SPRET/EiJ to provide novel insights in inflammation and infection research. Mamm Genome. 2018;29:585-592 pubmed publisher
    ..Now that the genome of SPRET/EiJ has been sequenced, and other tools have become available, it is time to revisit this strain and emphasize its advantages and disadvantages as a research tool and a discovery platform. ..
  5. Steeland S, Puimège L, Vandenbroucke R, Van Hauwermeiren F, Haustraete J, Devoogdt N, et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem. 2015;290:4022-37 pubmed publisher
    ..These results demonstrate the considerable potential of TROS and justify the evaluation of TROS in relevant disease animal models of both acute and chronic inflammation and eventually in patients. ..
  6. Van Wyngene L, Vandewalle J, Libert C. Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?. EMBO Mol Med. 2018;10: pubmed publisher
    ..In this review, we concentrate on the pathological changes in metabolism, observed during sepsis, and the presumed underlying mechanisms, with a focus on the level of the organism and the interplay between different organ systems. ..
  7. Steeland S, Libert C, Vandenbroucke R. A New Venue of TNF Targeting. Int J Mol Sci. 2018;19: pubmed publisher
    ..Here, we review the complications related to the use of conventional TNF inhibitors, together with the anti-TNF alternatives and the benefits of selective approaches in different diseases. ..
  8. Steeland S, Vandenbroucke R, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21:1076-113 pubmed publisher
    ..In addition, we highlight their potential for use in the diagnosis and monitoring of diseases. Finally, we provide an extended overview of Nbs that are, or have been, involved in clinical trials. ..
  9. De Bosscher K, Beck I, Ratman D, Berghe W, Libert C. Activation of the Glucocorticoid Receptor in Acute Inflammation: the SEDIGRAM Concept. Trends Pharmacol Sci. 2016;37:4-16 pubmed publisher

More Information

Publications15

  1. Van Hove I, Lefevere E, De Groef L, Sergeys J, Salinas Navarro M, Libert C, et al. MMP-3 Deficiency Alleviates Endotoxin-Induced Acute Inflammation in the Posterior Eye Segment. Int J Mol Sci. 2016;17: pubmed
    ..These findings suggest a contribution of MMP-3 during EIU, and its potential use as a therapeutic drug target in reducing ocular inflammation. ..
  2. Beyaert R, Libert C. How Good Roommates Can Protect against Microbial Sepsis. Cell Host Microbe. 2018;23:283-285 pubmed publisher
    ..They further identified gut microbial taxa that may account for the induction of this protective system. ..
  3. Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29:42-54 pubmed publisher
    ..In this review paper we discuss recent insights into GR-mediated actions in GCR and novel therapeutic strategies for acute and chronic inflammatory diseases. ..
  4. Souffriau J, Libert C. Mechanistic insights into the protective impact of zinc on sepsis. Cytokine Growth Factor Rev. 2018;39:92-101 pubmed publisher
    ..A full understanding of the mechanism of action of zinc may open new preventive and therapeutic interventions in sepsis. ..
  5. Puimège L, Van Hauwermeiren F, Steeland S, Van Ryckeghem S, Vandewalle J, Lodens S, et al. Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1. EMBO Mol Med. 2015;7:1004-17 pubmed publisher
  6. Van Cauwenberghe C, Vandendriessche C, Libert C, Vandenbroucke R. Caloric restriction: beneficial effects on brain aging and Alzheimer's disease. Mamm Genome. 2016;27:300-19 pubmed publisher
    ..However, additional research will be needed to determine the safety, efficacy, and usability of CR and its mimetics before a general recommendation can be proposed to implement them. ..